COMPANY
CAD Therapeutics, Inc.
CAD Therapeutics is developing Clonicaine, an investigational treatment for PTSD given with a physician-administered sympathetic-block procedure. Source · checked Oct 14, 2026
Sourced facts
Funding (SEC filing)
- SEC Form D filed Oct 2, 2026: $4,000,000 sold · sec.gov · checked Oct 14, 2026
Funding and NIH signals
- SEC Form D raise Raised $4M (Form D filed Oct 2, 2026). SEC Form D 0002157566-26-000001 (Oct 2, 2026)
Evidence (1 event)
- Oct 2, 2026 · SEC Form D 0002157566-26-000001
Name of Issuer: CAD Therapeutics, Inc.; CIK: 2157566; Address: New York, NY; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity, Other (SERIES A COMMON STOCK); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4000000; Federal exemptions: 06b
- Oct 2, 2026 · SEC Form D 0002157566-26-000001